Key publications

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia
Maciocia N, Hoekx M, Acuna C, Wade B, Burley A, Ramanayake S, Nannini F, Wawrzyniecka PA, Karpanasamy T, Schuldt M, Ng S, Ferrari M, Marafioti T, Gritti G, Onuoha S, O'Connor D, Lee L, Mansour M, Khwaja A, Pule M, Maciocia P. Sci Transl Med. 2025 Apr 16;17(794):eadr1476. doi: 10.1126/scitranslmed.adr1476. Epub 2025 Apr 16. PMID: 40238916.

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MAV, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS. J Clin Oncol. 2021 Aug 31:JCO2100917. doi: 10.1200/JCO.21.00917. Online ahead of print. PMID: 34464155

Chimeric antigen receptor T cells for gamma-delta T cell malignancies.
Wawrzyniecka PA, Ibrahim L, Gritti G, Pule MA, Maciocia PM. Leukemia. 2021 Aug 13. doi: 10.1038/s41375-021-01385-0. Online ahead of print. PMID: 34389804

Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Biasco L, Izotova N, Rivat C, Ghorashian S, Richardson R, Guvenel A, Hough R, Wynn R, Popova B, Lopes A, Pule M, Thrasher AJ, Amrolia PJ. Nat Cancer. 2021 Jun;2(6):629-642. doi: 10.1038/s43018-021-00207-7. Epub 2021 May 24. PMID: 34345830

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
Agliardi G, Anna Rita Liuzzi AR, Hotblack  A, De Feo D, Núñez  N, Stowe CL, Friebel E, Nannini  F, Rindlisbacher  L, Roberts TA, Ramasawmy R, Williams IP, Siow BM, Lythgoe MF, Kalber TL, Quezada SA, Pule MA, Tugues S, Straathof K, Becher B. Nat Commun. 2021 Jan 19;12(1):444. doi: 10.1038/s41467-020-20599-x.

Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Straathof K, Flutter B, Wallace R, Jain N, Loka N, Depani S, Wright G, Thomas S, Weng-Kit Cheung G, Gileadi T, Stafford S, Kokalaki E, Barton J, Marriott C, Rampling D, Ogunbiyi O, Akarca AU, Marafioti R, Inglott S, Gilmour K, Al-Hajj M, Day W, McHugh K, Biassoni L, Sizer N, Barton C, Edwards D, Dragoni I, Silvester J, Dyer K, Traub S, Elson L ,Brook S, Westwood N, Robson L, Bedi A, Howe K, Barry A, Duncan C, Barone G, Pule M, Anderson J. Sci Transl Med 2020 Nov 25;12(571):eabd6169. doi: 10.1126/scitranslmed.abd6169.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Ghorashian A, Kramer AM, Onuoha A, Wright G, Bartram J, Richardson R, Albon S, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Weng-Kit Cheung G, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Nat Med 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5.

A Rapamycin-Activated Caspase 9-Based Suicide Gene. Stavrou M, Philip B, Traynor-White C, Davis CG, Onuoha S, Cordoba S, Thomas S, Pule M. Mol Ther. 2018 May 2;26(5):1266-1276. doi: 10.1016/j.ymthe.2018.03.001.

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, Onuoha S, Thomas S, Baldan V, Bughda R, Maciocia P, Kokalaki E, Neves MP, Patel D, Rodriguez-Justo M, Francis J, Yong K, Pule M. Blood. 2018 Feb 15;131(7):746-758. doi: 10.1182/blood-2017-05-781351. Epub 2017 Dec 28.

Targeting the T cell receptor β-chain constant region for immunotherapy of T-cell malignancies. Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA. Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P. Sci Transl Med. 2017 Jan 25;9(374):eaaj2013. doi: 10.1126/scitranslmed.aaj2013.

Automated manufacturing of chimeric antigen receptor T-cells for adoptive immunotherapy using CliniMACS prodigy. Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W. Cytotherapy. 2016 Aug;18(8):1002-11. doi: 10.1016/j.jcyt.2016.05.009.

Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Duclert A, Gouble A, Arnould S, Peggs K, Pule M, Scharenberg AM, Smith J. Cancer Res. 2015 Sep 15;75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321. Epub 2015 Jul 16.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M. Blood. 2014 Aug 21;124(8):1277-87. doi: 10.1182/blood-2014-01-545020. Epub 2014 Jun 26.

Vaccination to improve the persistence of CD19CAR gene-modified T-cells in relapsed pediatric acute lymphoblastic leukemia. Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ. Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA. Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352.